Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protalix BioTherapeutics (PLX) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $8.3 million.

  • Protalix BioTherapeutics' Cost of Revenue fell 60.9% to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.3 million, marking a year-over-year decrease of 1034.18%. This contributed to the annual value of $24.3 million for FY2024, which is 581.76% up from last year.
  • Per Protalix BioTherapeutics' latest filing, its Cost of Revenue stood at $8.3 million for Q3 2025, which was down 60.9% from $5.9 million recorded in Q2 2025.
  • In the past 5 years, Protalix BioTherapeutics' Cost of Revenue registered a high of $9.5 million during Q2 2024, and its lowest value of $2.4 million during Q4 2022.
  • In the last 5 years, Protalix BioTherapeutics' Cost of Revenue had a median value of $4.9 million in 2023 and averaged $5.6 million.
  • Per our database at Business Quant, Protalix BioTherapeutics' Cost of Revenue surged by 26946.18% in 2023 and then plummeted by 5612.01% in 2024.
  • Protalix BioTherapeutics' Cost of Revenue (Quarter) stood at $3.1 million in 2021, then decreased by 23.86% to $2.4 million in 2022, then surged by 269.46% to $8.9 million in 2023, then crashed by 56.12% to $3.9 million in 2024, then skyrocketed by 114.2% to $8.3 million in 2025.
  • Its Cost of Revenue stands at $8.3 million for Q3 2025, versus $5.9 million for Q2 2025 and $8.2 million for Q1 2025.